GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » Net Cash per Share

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Net Cash per Share : $-0.14 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Harvard Apparatus Regenerative Technology's Net Cash per Share for the quarter that ended in Mar. 2024 was $-0.14.

The historical rank and industry rank for Harvard Apparatus Regenerative Technology's Net Cash per Share or its related term are showing as below:

During the past 13 years, the highest Price-to-Net-Cash Ratio of Harvard Apparatus Regenerative Technology was 274.67. The lowest was 0.91. And the median was 16.64.

HRGN's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.96
* Ranked among companies with meaningful Price-to-Net-Cash only.

Harvard Apparatus Regenerative Technology Net Cash per Share Historical Data

The historical data trend for Harvard Apparatus Regenerative Technology's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Apparatus Regenerative Technology Net Cash per Share Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 -0.34 -0.01 -0.04

Harvard Apparatus Regenerative Technology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.19 0.03 -0.04 -0.14

Competitive Comparison of Harvard Apparatus Regenerative Technology's Net Cash per Share

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Price-to-Net-Cash falls into.



Harvard Apparatus Regenerative Technology Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Harvard Apparatus Regenerative Technology's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.432-0.968-0)/13.9473
=-0.04

Harvard Apparatus Regenerative Technology's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.272-2.24-0)/13.9473
=-0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Harvard Apparatus Regenerative Technology Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Traded in Other Exchanges
N/A
Address
84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.
Executives
Junli He director C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling director 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc 10 percent owner C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard director 2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen director C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu officer: President C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr officer: Chief Financial Officer 14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green director, officer: See Remarks C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor officer: Chief Scientific Officer C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino officer: Interim VP of Finance C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez director 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge officer: See Remarks C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young director 60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang director C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li director C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746